$VAXX News
Last published 2y ago
- 2y agoVAXXVaxxinity Issues Shareholder LetterGlobeNewswireCAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced
- 2y agoVAXXVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockGlobeNewswireCAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced
- 2y agoVAXXVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingGlobeNewswireCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its
- 2y agoVAXXVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesGlobeNewswireCAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the
- 2y agoVAXXVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024GlobeNewswireLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in
- 2y agoVAXXVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedGlobeNewswirePreclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing,
- 2y agoVAXXVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024GlobeNewswireCAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its
- 2y agoVAXXVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaGlobeNewswireCAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University
- 2y agoVAXXVaxxinity Announces Collaboration on Space Medicine Research with University of Central FloridaGlobeNewswireCAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of
- 2y agoVAXXVaxxinity to Present at the 2024 J.P. Morgan Healthcare ConferenceGlobeNewswireCAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of
- 2y agoVAXXVaxxinity to Present at Upcoming November Medical and Investor ConferencesGlobeNewswireCAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will
- 3y agoVAXXVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireCAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended
- 3y agoVAXXVaxxinity to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireCAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of
- 3y agoVAXXVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's DiseaseGlobeNewswirePhase 2a data published in The Lancet's eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311
- 3y agoVAXXVaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific DirectorGlobeNewswireAppointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S.
- 3y agoVAXXVaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's PatientsGlobeNewswireDisease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson's patients Data provide validation of the Vaxxinity platform's ability to selectively
- 3y agoVAXXVaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's DiseaseGlobeNewswireUB-312 was immunogenic in patients with early Parkinson's disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support
- 3y agoVAXXVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireCAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the
- 3y agoVAXXVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in AprilGlobeNewswireVaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress UB-313 to be
- 3y agoVAXXVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireCAPE CANAVERAL, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the
- 3y agoVAXXVaxxinity Joins TransCelerate Research and Development ConsortiumGlobeNewswireCAPE CANAVERAL, Fla., March 21, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced today that it has joined
- 3y agoVAXXVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat HypercholesterolemiaGlobeNewswireCAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects
- 3y agoVAXXVaxxinity to Present at Upcoming March Scientific and Medical ConferencesGlobeNewswireCAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that its scientists and
- 3y agoVAXXICR Hosts Vaxxinity CEO Mei Mei Hu on the Welcome to the Arena PodcastBusiness WireICR, a leading strategic communications and advisory firm, is pleased to announce that Mei Mei Hu, Chief Executive Officer and Co-Founder, Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a
- 3y agoVAXXVaxxinity Announces Board Appointments and Establishes New Headquarters in FloridaGlobeNewswireAppointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE
- 3y agoVAXXVaxxinity to Present at the 2023 J.P. Morgan Healthcare ConferenceGlobeNewswireDALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer
- 3y agoVAXXVaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612GlobeNewswireVaxxinity's next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms:
- 4y agoVAXXVaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson's Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates UB-612
- 4y agoVAXXVaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022GlobeNewswireFeaturing subject matter experts in neuroscience, migraine and hypercholesterolemia DALLAS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of
- 4y agoVAXXVaxxinity to Present at Upcoming Investor Conferences in NovemberGlobeNewswireDALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer
- 4y agoVAXXVaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in AustraliaGlobeNewswireUB-612 Phase 3 topline data readout expected in 4Q22 DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines,
- 4y agoVAXXVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of MigraineGlobeNewswireDALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a Phase 1 clinical trial of UB-
- 4y agoVAXXVaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)GlobeNewswireDALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has initiated a rolling submission to the Medicines and Healthcare
- 4y agoVAXXVaxxinity to Present at Upcoming Investor Conferences in SeptemberGlobeNewswireDALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at the
- 4y agoVAXXVaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatesGlobeNewswire• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson's Completes Last Patient Last Dose, and Remains on Track to Complete an End-of-Treatment Analysis
- 4y agoVAXXVaxxinity to Present at the Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewswireDALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present at th
- 4y agoVAXXVaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human PrimatesGlobeNewswireResults support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterol VXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S.
- 4y agoVAXXVaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)GlobeNewswireDALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau pr
- 4y agoVAXXVaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 VaccinesGlobeNewswireSummit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET The White House Summit on the Future of COVID-19 Vaccines live webcast can be accessed here DALLAS, July 25, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX) Chief Execut
- 4y agoVAXXVaxxinity to Participate at the Jefferies Healthcare ConferenceGlobeNewswireDALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will p
- 4y agoCGEMMLSMRTSQSP+1Thinking about buying stock in Squarespace, Cullinan Oncology, Moneylion, SmartRent, or Vaxxinity?PR NewswireNEW YORK, May 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQSP, CGEM, ML, SMRT, and VAXX. To
- 4y agoVAXXVaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireDALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2022. "Vaxxinity h
- 4y agoVAXXVaxxinity to Participate at the Bank of America Securities 2022 Healthcare ConferenceGlobeNewswireDALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, President and Chief Executive Officer of Vaxxinity, will pa
- 4y agoCYNHPKRDBXVAXX+1Thinking about buying stock in Cyngn, Redbox Entertainment, Veru, Highpeak Energy, or Vaxxinity?PR NewswireNEW YORK, May 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CYN, RDBX, VERU, HPK, and VAXX. To s
- 4y agoVAXXVaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer's DiseaseGlobeNewswireDALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fas
- 4y agoVAXXVaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson's DiseaseGlobeNewswireResults from UB-312's Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, toda
- 4y agoVAXXCEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variantsGlobeNewswireOSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (NASDAQ:VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announ
- 4y agoVAXXVaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine BoosterGlobeNewswirePivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccines Agreement reached with global regulators on trial design and da
- 4y agoVAXXVaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdatesGlobeNewswireDALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2
- 4y agoVAXXVaxxinity Appoints Dr. Peter Powchik to Board of DirectorsGlobeNewswireDALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Dire